Background Clostridium difficile infection (CDI) can lead to complications, recurrence, and
death. Numerous studies have assessed risk factors for these unfavourable outcomes, but …

OBJECTIVEAn estimated 20–30% of patients with primary Clostridium difficile infection
(CDI) develop recurrent CDI (rCDI) within 2 weeks of completion of therapy. While the actual …

The objective of this review was to evaluate the frequency of treatment failure and
recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or …

C lostridium difficile is the leading cause of infectious nosocomial diarrhoea in developed
countries, with a measured incidence of approximately five episodes per 10 000 days of …

Clostridium difficile is a leading cause of hospital-acquired diarrhoea and represents a
major challenge for healthcare providers. Due to the decreasing efficacy and associated …

Resistance mechanism to metronidazole is still poorly understood, even if the number of
reports on Clostridium difficile strains with reduced susceptibility to this antibiotic is …

Clostridioides difficile is the leading cause of nosocomial infections and a worldwide urgent
public health threat. Without doubt, there is an urgent need for new effective anticlostridial …

Background Clostridium difficile is the leading cause of nosocomial infectious diarrhea.
Hospitalized patients were at risk of C. difficile-associated diarrhea (CDAD). However the …

Background Clostridium difficile infection (CDI) is a major health problem. Epidemiological
evidence suggests that there is an association between acid suppression therapy and …

Background Clostridium difficile infection (CDI) has increased in incidence and severity
worldwide, causing direct costs estimated to range from US 3.2billionto 4.8 billion. The aim …